<i>MECOM</i> fusion partner and bone marrow blast percentage influence outcomes of patients with <i>MECOM</i> rearranged acute myeloid leukaemiaWei‐Ying Jen, Tapan M. Kadia, Koji Sasaki et al.|British Journal of Haematology|2025Cited by 3
A comprehensive analysis of PCR for BCR::ABL1 and next-generation sequencing (NGS)-based measurable residual disease (MRD) with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): Prevalence, association with transcript type, and clinical outcomesManuel Maroun, Nicholas J. Short, Farhad Ravandi et al.|Blood|2025Cited by 2